Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation

Journal of Vascular Surgery
Gautam ShrikhandeAristidis Veves

Abstract

To examine the effect of a 12-week daily treatment with 160 mg of valsartan, an angiotensin II receptor blocker, on the microcirculation and macrocirculation of type 2 diabetic patients (T2DM) and healthy subjects. This was a prospective, randomized, double-blind, placebo-controlled crossover study. Thirteen T2DM with no severe complications and 13 healthy subjects completed the trial. Treatment with valsartan in T2DM improved the resting forearm skin blood flow and increased the resting brachial artery diameter but had no effects on arterial blood pressure, large vessel vascular reactivity, or carotid intima-media thickness. Resting skin blood flow increased by 60% (2%-90%; median and 25th-75th percentiles) during valsartan treatment and by only 2% (-22% to 27%) during placebo treatment (P < .05). No changes were observed in the nondiabetic subjects. Immunostaining studies of forearm skin biopsy samples from T2DM and healthy subjects showed that valsartan reduced poly(adenosine diphosphate-ribose) polymerase (PARP) activity in 50% (6/12) of the subjects. PARP activity remained unchanged in placebo-treated subjects (P < .02). In addition, valsartan treatment increased CD31 staining in 33% (4/12) of the subjects, whereas no chan...Continue Reading

References

Mar 1, 1996·Journal of the American College of Cardiology·S B WilliamsM A Creager
Dec 31, 1997·The Journal of Clinical Investigation·D G Harrison
Mar 31, 1999·Diabetes Care·S D RamseyE H Wagner
Oct 3, 2001·The Journal of Clinical Investigation·A M SchmidtD M Stern
Jan 15, 2002·Journal of the American College of Cardiology·Mary C CorrettiUNKNOWN International Brachial Artery Reactivity Task Force
Jul 26, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Joshua A BeckmanMark A Creager
Feb 7, 2004·The Journal of Clinical Endocrinology and Metabolism·Panayiotis A EconomidesAristidis Veves
Mar 17, 2004·Circulation·Riccardo CandidoKarin A Jandeleit-Dahm
Nov 27, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Jun AgataKazuaki Shimamoto

❮ Previous
Next ❯

Citations

Jan 29, 2011·Clinical and Experimental Hypertension : CHE·Tetsuro ShishidoIsao Kubota
Apr 27, 2010·Biochemical Pharmacology·Vincenzo GiansantiA Ivana Scovassi
Apr 21, 2009·Metabolism: Clinical and Experimental·Lalita KhaodhiarAristidis Veves
Jun 7, 2008·The American Journal of Pathology·Pal Pacher, Csaba Szabo
Feb 13, 2009·British Journal of Pharmacology·Csaba Szabo
Oct 7, 2011·The Journal of Clinical Hypertension·Kevin E C MeyersVictor Shi
Dec 7, 2013·Journal of Receptor and Signal Transduction Research·Tian-Biao Zhou, Zong-Pei Jiang
Nov 15, 2017·Human Reproduction Update·Constanze C MareschThomas Linn
May 15, 2013·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Jody R DushayAristidis Veves

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme
S D LuzioD R Owens
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Feng-jun ShenBao-en Wang
© 2022 Meta ULC. All rights reserved